Brett A King

List of Publications by Year in Descending Order

92 papers	2,676 citations	26 h-index	49 g-index
112 ext. papers	3,777 ext. citations	4.5 avg, IF	6.08 L-index

#	Paper	IF	Citations
92	Defining Severity in Alopecia Areata: Current Perspectives and a Multidimensional Framework.. *Dermatology and Therapy*, **2022**, 1	4	2
91	Two Phase 3 Trials of Baricitinib for Alopecia Areata.. *New England Journal of Medicine*, **2022**,	59.2	12
90	Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review. *Journal of the American Academy of Dermatology*, **2021**, 85, 735-736	4.5	8
89	Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. *Journal of the American Academy of Dermatology*, **2021**, 85, 743-745	4.5	11
88	A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome (PRO) measures. *British Journal of Dermatology* , **2021**,	4	1
87	The close resemblance between patients with severe alopecia areata and those with cancer: What hair tells us about wellness or grave illness. *Journal of the American Academy of Dermatology*, **2021**,	4.5	
86	It is all alopecia areata: It is time to abandon the terms alopecia totalis and alopecia universalis. *Journal of the American Academy of Dermatology*, **2021**,	4.5	1
85	A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS). *JAMA Dermatology*, **2021**, 157, 1-11	5.1	6
84	Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. *American Journal of Clinical Dermatology*, **2021**, 22, 395-405	7.1	9
83	Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis.. *JID Innovations*, **2021**, 1, 100021		2
82	Less is more? Failure of one JAK inhibitor does not predict failure of another one in a patient with alopecia areata. *Dermatologic Therapy*, **2021**, 34, e15062	2.2	
81	Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease. *JAAD Case Reports*, **2021**, 7, 44-46	1.4	3
80	Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1795-1809	11.5	10
79	The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 814-826	11.5	29
78	Ultraviolet light in combination with other therapies for vitiligo: Synergy or necessity?. *Journal of the American Academy of Dermatology*, **2021**, 84, e63-e64	4.5	1
77	The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. *Journal of the American Academy of Dermatology*, **2021**, 84, 1594-1601	4.5	7
76	Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. *JAAD Case Reports*, **2021**, 7, 122-124	1.4	3

75	A neutrophil activation signature predicts critical illness and mortality in COVID-19. *Blood Advances*, **2021**, 5, 1164-1177	7.8	93
74	Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims. *Advances in Therapy*, **2021**, 38, 4646-4658	4.1	7
73	Development of the alopecia areata scale for clinical use: Results of an academic-industry collaborative effort. *Journal of the American Academy of Dermatology*, **2021**,	4.5	7
72	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. *PLoS Biology*, **2021**, 19, e3001373	9.7	0
71	A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. *Journal of the American Academy of Dermatology*, **2021**, 85, 379-387	4.5	18
70	Electrocardiogram Findings in Patients with Alopecia Areata. *Dermatology and Therapy*, **2021**, 11, 2217-2223	4	
69	Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis. *JAAD Case Reports*, **2021**, 16, 62-64	1.4	3
68	Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study. *Journal of the American Academy of Dermatology*, **2021**, 85, 847-853	4.5	12
67	CD8 mycosis fungoides palmaris et plantaris with peripheral blood involvement. *JAAD Case Reports*, **2020**, 6, 434-437	1.4	1
66	When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. *Journal of the American Academy of Dermatology*, **2020**, 83, e269-e270	4.5	26
65	The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. *Journal of the American Academy of Dermatology*, **2020**, 83, 123-130	4.5	30
64	Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. *Journal of the American Academy of Dermatology*, **2020**, 83, 46-52	4.5	47
63	Development of the Scalp Hair Assessment PRO measure for alopecia areata. *British Journal of Dermatology*, **2020**, 183, 1065-1072	4	15
62	The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials. *British Journal of Dermatology*, **2020**, 183, 702-709	4	17
61	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. *British Journal of Dermatology*, **2020**, 183, 242-255	4	137
60	Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. *Journal of Investigative Dermatology*, **2020**, 140, 1446-1449.e4	4.3	12
59	Treatment of severe lichen planus with the JAK inhibitor tofacitinib. *Journal of Allergy and Clinical Immunology*, **2020**, 145, 1708-1710.e2	11.5	17
58	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. *Journal of the American Academy of Dermatology*, **2020**, 83, 839-846	4.5	30

57	The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Journal of the American Academy of Dermatology*, **2020**, 82, e223-e226	4.5	19
56	Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19. *Journal of the American Academy of Dermatology*, **2020**, 83, e67-e68	4.5	7
55	"Q You lose your hair, what's the big deal?Q I was so embarrassed, I was so self-conscious, I was so depressed:" a qualitative interview study to understand the psychosocial burden of alopecia areata. *Journal of Patient-Reported Outcomes*, **2020**, 4, 76	2.6	11
54	The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature. *Yale Journal of Biology and Medicine*, **2020**, 93, 187-195	2.4	11
53	Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid. *JAAD Case Reports*, **2020**, 6, 133-135	1.4	8
52	Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study. *Journal of Investigative Dermatology Symposium Proceedings*, **2020**, 20, S62-S68	1.1	6
51	Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. *Journal of the American Academy of Dermatology*, **2020**, 82, 612-621	4.5	50
50	Treatment of Multiorgan Sarcoidosis With Tofacitinib. *ACR Open Rheumatology*, **2020**, 2, 106-109	3.5	28
49	Treatment of granuloma annulare with tofacitinib 2% ointment. *JAAD Case Reports*, **2020**, 6, 69-71	1.4	12
48	Eyebrows Are Important in the Treatment of Alopecia Areata. *Journal of Investigative Dermatology Symposium Proceedings*, **2020**, 20, S37-S40	1.1	1
47	The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms. *Journal of Investigative Dermatology Symposium Proceedings*, **2020**, 20, S71-S77	1.1	2
46	Perniolike lesions and coagulopathy in a patient with COVID-19 infection. *JAAD Case Reports*, **2020**, 6, 1294-1296	1.4	4
45	Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. *American Journal of Clinical Dermatology*, **2020**, 21, 725-732	7.1	12
44	Reply to: "Comment on Q Rule of thumb: A simple tool to estimate 1% scalp surface areaQ Whose thumb is it anyway?". *Journal of the American Academy of Dermatology*, **2019**, 81, e185	4.5	
43	IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. *Journal of Allergy and Clinical Immunology*, **2019**, 144, 1731-1734.e1	11.5	5
42	Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies-Taming T REX. *JAMA Dermatology*, **2019**, 155, 283-284	5.1	2
41	Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata. *Journal of the American Academy of Dermatology*, **2019**, 80, 1778-1779	4.5	6
40	Rule of thumb: A simple tool to estimate 1% scalp surface area. *Journal of the American Academy of Dermatology*, **2019**, 81, 630-631	4.5	5

39	Treatment of severe alopecia areata with baricitinib. *JAAD Case Reports*, **2019**, 5, 892-894	1.4	16
38	Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib. *JAAD Case Reports*, **2019**, 5, 1018-1026	1.4	12
37	Rethinking the classification of alopecia areata. *Journal of the American Academy of Dermatology*, **2019**, 80, e45	4.5	10
36	Ruxolitinib for the treatment of severe alopecia areata. *Journal of the American Academy of Dermatology*, **2019**, 80, 566-568	4.5	24
35	Tofacitinib for the treatment of alopecia areata in preadolescent children. *Journal of the American Academy of Dermatology*, **2019**, 80, 568-570	4.5	22
34	Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families. *Journal of the American Academy of Dermatology*, **2018**, 79, 556-558.e1	4.5	29
33	Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy. *JAMA Dermatology*, **2018**, 154, 370-371	5.1	31
32	Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. *Journal of the American Academy of Dermatology*, **2018**, 78, 403-404.e1	4.5	37
31	Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. *Journal of the American Academy of Dermatology*, **2018**, 78, 597-599.e2	4.5	5
30	Repeat Conjunctival Biopsy after Immunomodulatory Therapy for Ocular Mucous Membrane Pemphigoid. *Ocular Immunology and Inflammation*, **2018**, 26, 70-73	2.8	
29	A 71-year-old man with a hemorrhagic vesicular eruption. *International Journal of Dermatology*, **2018**, 57, 147-148	1.7	1
28	Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. *New England Journal of Medicine*, **2018**, 379, 2540-2546	59.2	87
27	Cicatrizing Blepharoconjunctivitis Occurring During Dupilumab Treatment and a Proposed Algorithm for Its Management. *JAMA Dermatology*, **2018**, 154, 1485-1486	5.1	20
26	Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. *JAAD Case Reports*, **2018**, 4, 443-445	1.4	39
25	Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis. *JAAD Case Reports*, **2017**, 3, 4-6	1.4	19
24	JAK inhibitors in dermatology: The promise of a new drug class. *Journal of the American Academy of Dermatology*, **2017**, 76, 736-744	4.5	207
23	Lack of efficacy of apremilast in 9 patients with severe alopecia areata. *Journal of the American Academy of Dermatology*, **2017**, 77, 773-774	4.5	17
22	Keratosis lichenoides chronica successfully treated with isotretinoin and methotrexate. *JAAD Case Reports*, **2017**, 3, 205-207	1.4	6

21	Tofacitinib for the treatment of alopecia areata and variants in adolescents. *Journal of the American Academy of Dermatology*, **2017**, 76, 29-32	4.5	102
20	Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. *Journal of the American Academy of Dermatology*, **2017**, 76, 22-28	4.5	170
19	Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. *Journal of Investigative Dermatology*, **2017**, 137, 951-954	4.3	46
18	Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. *Journal of the American Academy of Dermatology*, **2016**, 75, 806-812.e3	4.5	71
17	STATing the obvious: it's time for new treatments in atopic dermatitis. *British Journal of Dermatology*, **2016**, 175, 861-862	4	
16	Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. *JAMA Dermatology*, **2016**, 152, 492-3	5.1	53
15	Topical Ruxolitinib for the Treatment of Alopecia Universalis. *JAMA Dermatology*, **2016**, 152, 490-1	5.1	79
14	Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. *JCI Insight*, **2016**, 1, e89776	9.9	167
13	Idiopathic erythema multiforme: Evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib. *JAAD Case Reports*, **2016**, 2, 502-504	1.4	10
12	Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream. *JAAD Case Reports*, **2016**, 2, 114-6	1.4	9
11	Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. *Blood*, **2016**, 127, 948-51	2.2	42
10	Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. *Journal of the American Academy of Dermatology*, **2015**, 73, 395-9	4.5	147
9	Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. *JAMA Dermatology*, **2015**, 151, 1110-2	5.1	156
8	Purpuric Lesions on Acral Sites. Type I cryoglobulinemia associated with multiple myeloma. *JAMA Dermatology*, **2015**, 151, 659-60	5.1	1
7	Psychophysical measurements of itch and nociceptive sensations in an experimental model of allergic contact dermatitis. *Journal of Pain*, **2015**, 16, 741-9	5.2	20
6	Divalproex sodium: A potential therapy for scleroderma digital ulcers. *JAAD Case Reports*, **2015**, 1, 44-5	1.4	2
5	Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. *Journal of Investigative Dermatology*, **2014**, 134, 2988-2990	4.3	134
4	A unilateral orbital mass. *JAMA Dermatology*, **2014**, 150, 1115	5.1	

3	Atypical hand-foot-and-mouth disease associated with coxsackievirus A6 infection. *Journal of the American Academy of Dermatology*, **2013**, 69, 736-741	4.5	57
2	Serum sickness-like reaction: histopathology and case report. *Journal of the American Academy of Dermatology*, **2011**, 65, e83-e85	4.5	20
1	Palifermin-associated papular eruption. *Archives of Dermatology*, **2009**, 145, 179-82		7